| text 
Clomicalm® (Clomipramine)
Product information on this website is for Non-U.S. residents only and is provided by Novartis Animal Health Inc. for general purposes only. Many veterinary products listed are available upon prescription only, and not all such products may be available in all countries. The product information is not intended to provide complete medical information. SHOULD YOUR ANIMAL HAVE A MEDICAL CONDITION, PROMPTLY SEE YOUR OWN VETERINARIAN. WE DO NOT OFFER PERSONALIZED MEDICAL DIAGNOSIS OR ANIMAL-SPECIFIC TREATMENT ADVICE. You should always obtain complete medical information about your veterinary product prescription (including their beneficial medical uses and possible adverse effects) by discussing the appropriate use of any veterinary product directly with the prescribing veterinarian.
Veterinary professionals may obtain complete medical information from the product's information leaflet. Information on these products may vary by country. Animal owners and veterinarians should check with local medical resources and regulatory authorities for information appropriate to their country. In addition, current regulations in many countries limit (or even prohibit in some instances) the ability of Novartis Animal Health Inc. to provide information and/or to respond directly to questions regarding its prescription products. Novartis Animal Health Inc., however, will respond to inquiries from and provide information to your qualified health care professional in accordance with local regulations.
Description
Product Type
Oral tablets as an aid in the treatment of separation-related disorders in dogs.
Description and Composition
Oral, beef flavored tablets of 4 strengths are available:
CLOMICALM 5, 20, 40 and 80 contain 5.00 mg, 20.00 mg 40.00 mg and 80.00 mg clomipramine hydrochloride, respectively. (Approved strengths vary by country)
Properties
Clomipramine hydrochloride, the active ingredient of CLOMICALM, has a broad-spectrum of action in blocking the reuptake of neurotransmitters. Clomipramine hydrochloride’s capacity to inhibit re-uptake of serotonin in the central nervous system is believed to be the primary mechanism of action. Clomipramine has, in addition, anticholinergic effects.
CLOMICALM possesses anxiolytic properties and has a very limited sedative effect, thus maintaining the dog’s ability to learn new behaviors.
Indications
As an aid in the treatment of separation-related disorders manifested by destruction and inappropriate elimination (defecation and urination) in combination with behavioral modification techniques.
In some countries, CLOMICALM is also authorized for the control of stereotypies in dogs or of urine spraying in cats.
Dosage and Administration
CLOMICALM is administered orally at a dose of 1 - 2 mg/kg clomipramine twice daily to give a total daily dose of 2 - 4 mg/kg according to the following table:
|
Body weight |
Dosage per administration |
||
|
Clomicalm 5 mg |
Clomicalm 20 mg |
Clomicalm 80 mg |
|
|
1.25 - 2.5 kg |
0.5 tablet |
||
|
>2.5 - 5 kg |
1 tablet |
||
|
>5 - 10 kg |
0.5 tablet |
||
|
>10 - 20 kg |
1 tablet |
||
|
>20 - 40 kg |
0.5 tablet |
||
|
>40 - 80 kg |
1 tablet |
||
CLOMICALM may be given with or without food. Usually, a treatment time of 2-3 months with CLOMICALM in combination with behavioral modification techniques is sufficient to control the symptoms of separation-related disorders. Some cases may require longer treatment. In cases showing no improvement after 2 months, treatment with CLOMICALM should be ceased.
Special Precautions and Warnings
The use of CLOMICALM is not authorized in breeding dogs. In dogs with cardiovascular dysfunction, epilepsy, narrow angle glaucoma, reduced gastrointestinal motility or urinary retention, CLOMICALM should be given with caution and only after an assessment of the benefit risk ratio.
CLOMICALM may potentiate the effects of CNS active drugs. CLOMICALM should not be used in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold. The administration of CLOMICALM is not recommended in combination with, or within 2 weeks of therapy with, monoamine oxidase inhibitors.
Formulations and Packages
The 4 tablet strengths are available in color-coded packs containing HDPE bottles with child resistant closure and sealing disk, each containing 30 tablets and a silica gel desiccant.
Product Availability
Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local veterinarian for local prescribing and any other information you may be interested in.
U.S. Residents
This is an international website and is intended for residents outside the US.
If you are a Consumer or Veterinarian in the USA and have questions about our products, please call:
Novartis Technical Product Services Group
1-800-637-0281
Partnerships
Novartis collaborates with many companies and academic institutions to develop new products, acquire platform technologies, and access new markets.
Locations
Headquartered in Basel, Switzerland, and present in almost 40 countries, Novartis Animal Health employs approximately 2,700 associates worldwide.
